PFS表示的是维持病情稳定的时间,时间越长,表明受益越大。 肿瘤评估往往是间隔一段时间做一次的,比如说6周± 7天评估一次。这就表明,PD日期,并不是一个客观的事物变化的日期,而是一个主观的去观察事物变化的日期。当观察到PD时,实际上表示在上一次评估和当前评估之间的某个时间点发生了疾病进展。 由此导致PFS容易...
“PFS是Progression-Free-Survival的缩写,中文意思就是无进展生存时间,所代表的就是癌症患者从开始接受治疗,到出现疾病进展情况或者是因为各种原因出现死亡的这段时间,是现在临床上用于判断恶性肿瘤患者生存情况的重要指标,PFS时间越长就表示患者生存周期越长,时间短则表示生存周期短。 肿瘤ORR指的是客观缓解率,学术说法...
网络进展生存 网络释义 1. 进展生存 ...erall survival OS)率,6年无疾病进展生存(Progression free survival PFS)率;对用药后的常见不良反应进行分析总结,了解慢性 … cdmd.cnki.com.cn|基于 1 个网页 释义: 全部,进展生存
PFS 无进展生存期(progression-free survival) rPFS放射影像学无进展生存率 DCR 疾病控制率(disease control rate) ORR 客观缓解率(Objective Response Rate) OR 总缓解率 (overall response 或者 overall remission) PD 疾病进展(progression disease) MTD 最大耐受剂量(maximum tolerated dose) PD:疾病进展( progressi...
评估进步自由的生存(PFS)和整体生存(OS)。 翻译结果5复制译文编辑译文朗读译文返回顶部 评估无进步生存 (PFS) 和整体生存 (OS)。 相关内容 ai also great and would suffice i也伟大,并且将足够了 [translate] amax temperature resistance 最高温度抵抗 [translate] aDETOX +CLEANSE+BALANCE DETOX +CLEANSE+BALANC...
Progression-free survival (PFS) is defined as the time from entry onto study until lymphoma progression or death from any cause. PFS is often the preferred endpoint in lymphomaclinical trials, especially those involving incurable or indolent histologies, because it reflects tumor growth and therefore...
The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall response (OR), complete response (CR), overall and 3 year survival, and safety. The primary analysis was based on the independent response review panel's (IRRP) assessment of response and date of ...
(PFS) when compared with placebo, in all patients or in patients with EGFR immunohistochemistry (IHC) positive tumors. 研究的最初目标是决定如果 TARCEVA 的管理在 NSCLC 的治疗中的标准基于白金的化疗免费导致被改善的级数后继续生存 (PFS) 被与安慰剂比较时,在有 EGFR immunohistochemistry 的病人中或在...
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients wit... Progression- free survival (PFS) by blinded independent central review (BICR) and updated overall survival (OS) of sunitinib versus placebo...